We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
09 Dec 2022 - 11 Dec 2022

First-Ever AI Test for Early Diagnosis of Alzheimer’s to Be Expanded to Diagnosis of Parkinson’s Disease

By HospiMedica International staff writers
Posted on 05 Nov 2021
Print article
Illustration
Illustration

A new partnership will accelerate development of the industry’s first predictive device for Alzheimer’s Disease to be expanded to diagnosis of Parkinson’s disease.

Altoida, Inc. (Washington, DC, USA) has entered into a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics, at the Ionian University (Corfu, Greece) to investigate Altoida’s medical device, an FDA Breakthrough Device being developed for early diagnosis and monitoring of Alzheimer’s disease, for early diagnosis and prediction of Parkinson’s disease onset. BiHELab is a research center specializing in the application of mathematical modeling and machine learning techniques to neurodegenerative diseases, like Parkinson’s and Alzheimer’s.

With a 10-minute series of augmented reality and digital motor activities that simulate complex activities of daily living, Altoida transforms any smartphone or tablet into the world’s most powerful medical device to assess neurocognitive function. The company won Breakthrough Designation for development of their device to use artificial intelligence to help predict conversion to Alzheimer’s, and they secured funding from the Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator to test their device for diagnosis in the preclinical phase of Alzheimer’s.

The three-year collaboration will kick off with the launch of the Digital Innovation HUB: Health Hub, a public-private partnership with 25 participating entities dedicated to fostering healthcare research and innovation in Greece. In that time, Altoida and BiHELab will apply and Altoida’s technology to analysis of Parkinson’s disease progression and evaluate its efficacy in diagnosing Parkinson’s in the preclinical phase.

"This is recognition of the strong clinical need for early diagnosis of Parkinson's disease, which could enable preventive and therapeutic intervention in the early stages to delay onset and improve clinical outcomes," said Ioannis Tarnanas, Ph.D., Chief Scientific Officer of Altoida. “We are excited to collaborate with BiHELab to further develop our technology, and to engage with the Health Hub’s scientific network to bring this application to life for the Greek population.”

"By applying innovative bioinformatics and machine learning techniques to clinical data, BiHeLab has aimed to identify novel biomarkers that are most indicative of risk of Parkinson’s disease,” said Professor Panagiotis Vlamos, Scientific Director at BiHELab. “For Parkinson’s patients, accurate prediction and early diagnosis could enable intervention before the extensive damage of dopaminergic neurons occurs."

Related Links:
Altoida, Inc. 
Ionian University 

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
Hematology Workflow Solution
DIFF-Line
New
Fecal Occult Blood Test
iFOB Assay
New
Chlamydia Infection Diagnostic Test
Chlamydia Test

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: The genetically engineered FcMBL protein can capture more than 100 different microbial species (Photo courtesy of Wyss Institute)

Rapid Pathogen Capture Technology Could Accelerate Diagnosis of Bloodstream Infections and Sepsis

Bloodstream infections (BSIs) with various microbial pathogens can rapidly escalate to life-threatening sepsis when the body is overwhelmed by the multiplying invaders and shuts down its organs’ functions.... Read more

Surgical Techniques

view channel
Image: CystoSmart image enhancement and AI diagnostic tool will enhance cancer detection (Photo courtesy of Claritas HealthTech)

AI Diagnostic Tool Improves Cancer Detection in Cystoscope Images of Bladder

Bladder cancer is the 10th commonest cancer worldwide and the 6th commonest cancer amongst men. It is known to have high recurrence rates and significant risks of disease progression. Early detection of... Read more

Patient Care

view channel
Image: Automated cleaning system allows endoscopes to be cleaned direct from clinic (Photo courtesy of Aston University)

World’s First Automated Endoscope Cleaner Fights Antimicrobial Resistance

Endoscopes are long, thin tubes with a light and camera at one end. Due to the sensitivity of the materials and electronics they cannot be sterilized in an autoclave (a machine that uses steam under pressure),... Read more

Business

view channel
Image: The global multiparameter patient monitoring systems market is expected to surpass USD 15 billion by 2028 (Photo courtesy of Unsplash)

Global Multiparameter Patient Monitoring Systems Market Driven by Rising Chronic Illnesses

Multi-parameter patient monitoring equipment is used to assess the vital signs of patients who are suffering from a serious illness. These devices are meant to give the number of data sets on one screen... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.